COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01850446
Recruitment Status : Completed
First Posted : May 9, 2013
Results First Posted : April 3, 2020
Last Update Posted : April 16, 2020
Information provided by (Responsible Party):
Materia Medica Holding

Brief Summary:

The purpose of this study is:

  • to assess the efficacy of Ergoferon in treatment of influenza;
  • to assess the safety of Ergoferon in treatment of influenza;
  • to compare the efficacy of Ergoferon and Oseltamivir for treatment of influenza.

Condition or disease Intervention/treatment Phase
Influenza Drug: Ergoferon Drug: Oseltamivir Phase 4

Detailed Description:
The overall duration of a patient participation in the trial is 6 days (screening/randomization/therapy onset - day 1; study therapy period - day 1-5; follow-up period - day 6).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 184 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparative Parallel-group Randomized Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza
Actual Study Start Date : February 20, 2015
Actual Primary Completion Date : April 16, 2018
Actual Study Completion Date : April 16, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot
Drug Information available for: Oseltamivir

Arm Intervention/treatment
Experimental: Ergoferon
The treatment period is 5 days. Oral Dose per administration: 1 tablet. The tablet should be kept in the mouth until completely dissolution, the drug is taken without regard to food intake.
Drug: Ergoferon
Safety and Efficacy

Active Comparator: Oseltamivir (Tamiflu)

The treatment period is 5 days.

1 capsule (75 mg) twice a day during the meal or regardless of meal.

Drug: Oseltamivir
Safety and Efficacy
Other Name: Tamiflu

Primary Outcome Measures :
  1. Percentage of Patients With Recovery/Improvement in Health Status. [ Time Frame: On 2-7 days of observation ]
    Based on days 2-7 days of observation according to the patient's diary, and on days 3 and 7 according to the physician's examination.

Secondary Outcome Measures :
  1. Changes in Fever. [ Time Frame: Baseline and days 2-7 of the observation ]
    Fever changes over time (body temperature change on days 2-7 compared to baseline, based on patient diary data).

  2. Average Duration of Fever. [ Time Frame: From the time of randomization until the time of recovery/improvement (days 1-7) ]
    Criteria of no fever - body temperature lower than 37.0° C for 24 hours

  3. Percentage of Patients With Normal Body Temperature. [ Time Frame: Days 2-7 of the observation ]
    Based on patient's diary. Normal body temperature is no more than 37.0ºС.

  4. Severity of Influenza Symptoms (Fever, Flu Non-specific and Nasal/Throat/Chest Symptoms) in Scores According to the Symptoms Severity Scale. [ Time Frame: On 1-7 days of observation ]

    The symptoms severity scale includes 14 symptoms: body temperature, non-specific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness), nasal/throat/chest symptoms (runny nose, stuffy nose, sneezing, sore throat, hoarseness, cough, chest pain).

    The severity of each non-specific and nasal/throat/chest symptom is scored on a 4-point scale (0=no symptom; 1=mild symptom; 2=moderate symptom; 3=severe symptom). The minimum value of each symptom is 0 points, and the maximum value is 4 points.

    The absolute body temperature (in degrees Celsius) is converted to relative units (or scores) using the following scale: ≤37.2С=0 points; 37.3-38.0С=1 point; 38.1-39.0С=2 points; ≥39.1С=3 points.

    The severity of symptoms is based on the physical examination of the patient by the physician on days 1, 3, and 7 and on the patient diary data on days 1-7. The minimum symptoms severity score is 0 points, the maximum score is 42 points.

  5. Duration of Clinical Symptoms of Influenza (Fever, Non-specific Symptoms and Nasal/ Throat/ Chest Symptoms) in Days. [ Time Frame: On 1-7 days of observation ]
    Duration of clinical symptoms of influenza (fever, non-specific symptoms and nasal/ throat/ chest symptoms) in days based on the result of the patient's diary data

  6. The Severity of Influenza. [ Time Frame: On days 1-7 of the observation. ]
    Based on the patient diary. The severity of influenza based on the data on the "Area Under Curve" for total index of influenza severity.

  7. Percentage of Patients Who Used Antipyretics on Days 1, 2, 3, 4 and 5 of the Treatment. [ Time Frame: Days 1, 2, 3, 4 and 5 of the treatment ]

    Antipyretics, which are allowed for use during clinical trial, are:

    1. Paracetamol;
    2. Metamizole sodium (if hyperthermia was not stopped by usage of paracetamol).

  8. Percentage of Patients Requiring Antibiotics Administration. [ Time Frame: On 1-7 days of observation. ]

    Based on patient's diary, objective examination (according to physician's objective examination).

    The patients with the development of disease complications and exacerbation of the disease course (the development of severe influenza).

  9. Proportion of Patients With Negative Results of Virological Analysis. [ Time Frame: On days 3, 5, 7 of observation. ]
    Based on medical records of patients whose nasopharyngeal swabs submitted for Reverse Transcription Polymerase Chain Reaction (RT-PCR) were negative for influenza A/B virus.

  10. Dynamics of Parameters of Immune Status (T-cell and B-cell Immune Response). [ Time Frame: On days1, 3 and 7 of observation. ]
    The concentration of regulators of the T-cell immune response (IL2, IFN -γ, IL-18), and regulators of В-cell immune response (IL-4, IL-16).

  11. Dynamics of Parameters of Immune Status ( IFN-α and IFN-γ Production). [ Time Frame: On day 1, 3 and 7 of observation. ]
    Level of spontaneous and induced production of IFN-α and IFN-γ (in vitro).

  12. Dynamics of Parameters of Immune Status (Absolute Number of Each Type of White Blood Cells and Different Lymphocyte Phenotypes). [ Time Frame: On days 1, 3 and 7 of observation. ]
    The absolute number of each type of white blood cells (WBC): Absolut Count (AC) of leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and CD3, CD4, CD8, CD4/CD8, CD16, CD119 leukocytes.

  13. Dynamics of Parameters of Immune Status (Relative Percentage of Each Type of White Blood Cells and Different Lymphocyte Phenotypes). [ Time Frame: On days 1, 3 and 7 of observation. ]
    The relative percentage of each type of white blood cells (WBC): Relative Count (AC) of leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and CD3, CD4, CD8, CD4/CD8, CD16, CD119 leukocytes.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients aged 18 to 70 years.
  2. Patients who were admitted to hospital within 48 hours from the onset of influenza signs.
  3. Patients with body temperature ≥37,8°C when visiting a doctor + severity of influenza symptoms ≥4 scores (presence of at least 1 non-specific flu symptom ≥2 scores and 1 nasal/ throat/ chest symptom ≥ 2 scores or greater number of symptoms with the severity ≥1 score).
  4. Diagnosed influenza confirmed by rapid diagnostic test (OSOM Influenza A&B Test).
  5. The possibility to start therapy within 48 hours after the onset of the first symptoms of influenza.
  6. Usage of contraceptive methods by both gender patients of reproductive age during the trial and within 30 days after ending the participation in the trial.
  7. Availability of signed patient information sheet (Informed Consent form) for participation in the clinical trial.

Exclusion Criteria:

  1. Suspected pneumonia, bacterial infection or the presence of a severe disease requiring usage of antibacterial drugs (including sulphanilamides) starting from Day 1 of the disease.
  2. Severe influenza with indications for hospitalization.
  3. Suspected early manifestations of diseases that have symptoms similar to influenza symptoms (other acute respiratory and infectious diseases, influenza-like syndrome at the onset of systemic connective tissue disorders, hematologic neoplasms and other pathology).
  4. Patients requiring concurrent antiviral products forbidden by the study.
  5. Medical history of primary and secondary immunodeficiencies. а) lymphoid immunodeficiencies (Т-cell and/or В-cell, immunodeficiencies with predominant antibody deficit); b) phagocytic deficits; c) complement factor deficit; d) combined immunodeficiencies including AIDS secondary to HIV infection; toxic, autoimmune, infectious, radiation panleukopenic syndrome; total lymphocytopenic syndrome; polyclonal lymphocyte activation syndrome; postsplenectomic syndrome; congenital asplenia; abnormal immune complex syndrome associated with infectious, autoimmune and allergic diseases.
  6. Medical history of sarcoidosis
  7. An oncological disease/suspected oncological disease.
  8. Exacerbated or decompensated chronic diseases affecting a patient's ability to participate in the clinical trial.
  9. Medical history of polyvalent allergy.
  10. Allergy/intolerance to any of the components of the product used for influenza therapy.
  11. Impaired glucose tolerance, type 1 and type 2 diabetes mellitus.
  12. Malabsorption syndrome, including congenital or acquired lactose deficiency or another disaccharide deficiency.
  13. Pregnancy, breast-feeding.
  14. Consumption of narcotics, alcohol > 2 alcohol units per day, mental diseases.
  15. Use of any medicine listed in the section "Prohibited concomitant treatment" within 30 days preceding the inclusion in this study.
  16. Patients who, from the investigator's point of view, will fail to comply with the observation requirements of the trial or with the regimen of the study drugs.
  17. Participation in other clinical studies within 1 month prior to enrollment in the current trial.
  18. Patients related to the research staff of the clinical trial site who are directly involved in the trial or are the immediate family member of the researcher. The immediate family members include husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted.
  19. Patients employed with OOO "NPF "MATERIA MEDICA HOLDING" (i.e., the company's employee, part-time employee under contract, or appointed official in charge of the trial, or their immediate family).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01850446

Layout table for location information
Russian Federation
The Non-State Health Care Institution "Road Hospital of the Open Joint Stock Company" Russian Railways"
Chelyabinsk, Russian Federation, 454091
The State Budgetary Educational Institution of Higher Professional Education " Kazan State University of Medicine" Ministry of Health of the Russian Federation
Kazan, Russian Federation, 420012
Pirogov Russian National Research Medical University
Moscow, Russian Federation, 117997
Limited Liability Company "Scientific Research Centre Eco-safety"
Saint Petersburg, Russian Federation, 196143
Regional State Budgetary Healthcare Institution "Clinical Hospital №1"
Smolensk, Russian Federation, 214006
Federal State Budgetary Military Educational Institution of Higher Professional Education "Military-Medicine Academy named after S. M. Kirov" of Ministry of Defence of Russian Federation
St. Petersburg, Russian Federation, 194044
St. Petersburg State Budgetary Health Care Institution " City policlinic No. 117"
St. Petersburg, Russian Federation, 194358
Sponsors and Collaborators
Materia Medica Holding
  Study Documents (Full-Text)

Documents provided by Materia Medica Holding:
Layout table for additonal information
Responsible Party: Materia Medica Holding Identifier: NCT01850446    
Other Study ID Numbers: MMH-ER-003
First Posted: May 9, 2013    Key Record Dates
Results First Posted: April 3, 2020
Last Update Posted: April 16, 2020
Last Verified: January 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action